PCC
LXRX icon

Park Circle Company’s Lexicon Pharmaceuticals LXRX Stock Holding History

Park Circle Company’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-21,000
Closed -$251K – 91
2016
Q1 		$251K Buy
+21,000
New +$220K 0.19% 53

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Park Circle Company's LXRX Position: Q2 2016 in Review

Park Circle Company sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2016, closing a stake of 21,000 shares — an estimated $251K sold.

Park Circle Company first reported a position in LXRX in Q1 2016 and held it in 1 quarter. The position peaked at $251K in Q1 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q2 2016.

  • Park Circle Company reported no remaining Lexicon Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Park Circle Company sold 21,000 Lexicon Pharmaceuticals shares in Q2 2016, an estimated $251K.
  • Park Circle Company first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Park Circle Company's Lexicon Pharmaceuticals position peaked at $251K in Q1 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2016.

Based on Park Circle Company's 13F filing for Q2 2016, filed 21 Jul 2016.